Skip to search formSkip to main contentSkip to account menu

ARN-810

Known as: SERD ARN-810, Selective Estrogen Receptor Degrader ARN-810 
An orally available, nonsteroidal selective estrogen receptor degrader (SERD), with potential antineoplastic activity. Upon oral administration, SERD… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
Approximately 80% of breast cancers are estrogen receptor alpha (ER-α) positive, and although women typically initially respond… 
2015
2015
Background: Modulation of estrogen activity and/or synthesis is the mainstay therapeutic strategy in the treatment of estrogen… 
2015
2015
Background: Evidence that ER can signal in both ligand-dependent and independent manner in endocrine resistant breast cancer (BC… 
2015
2015
Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA The majority of breast cancers express estrogen… 
2015
2015
The majority of breast cancers express and rely on ERα for tumor growth, thus endocrine therapy is the mainstay of ER-positive… 
2014
2014
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA 80% of all breast cancers express the estrogen receptor… 
2013
2013
Background: Modulation of estrogen synthesis or its receptor activity represents the treatment of choice for postmenopausal women… 
2013
2013
Penelitian ini menggunakan metode eksperimen.Populasi dalam penelitian ini adalah seluruh siswa kelas X SMK Teknik Rekayasa Sinar…